The ETC payment model will encourage access to and adoption of home dialysis over the next five years. Baxter Reports Third-Quarter 2020 Results, Supported a new investigator-initiated study, Announced U.S. Food and Drug Administration (FDA), Received U.S. FDA Emergency Use Authorizations (EUAs) for Baxter's, Announced a distribution agreement with bioMérieux, a global leader in in vitro diagnostics, for the. Our portfolio of acute, nutritional, renal, hospital and surgical care products helps advance healthcare around the world. 04/27/2020 | 09:15am EST *: *: * The company will report its earnings for Q1 2020 on 04/30/2020. When every moment counts, our therapies help healthcare specialists provide life-sustaining treatment to you or your loved one. Baxter expects GAAP earnings from continuing operations of $0.75 to $0.78 per share and adjusted earnings from continuing operations, before special items, of $0.82 to $0.84 per diluted share. Our more than 85-year heritage gives us distinct perspective on the needs of patients and caregivers. Price to Earnings Ratio vs. the Market The P/E ratio of Baxter International is 45.18, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.74. Among recent highlights, the company: Building on Baxter’s strong diversity and inclusion platform, senior leadership is working in close collaboration with the Baxter Black Alliance business resource group and colleagues from across the company on a multidimensional program to advance inclusion and racial justice. =�e.m�r}�IN|���ޣ�Bk��k#��{ �W��Q�cy �#}D�����B�6E�i3����T. 3 0 obj $0.67 (3%) diluted: $0.64. "Baxter's third-quarter performance reflects ongoing demand for our medically essential products as well as the company’s agility and resilience amid a historic public health crisis," said José (Joe) E. Almeida, chairman and chief executive officer. ESG & Corporate Responsibility. Third-quarter sales of $2.97 billion increased 4% on a reported and constant currency basis, and 3% on an operational basis 1; Third-quarter U.S. GAAP earnings per share (EPS) of $0.69 decreased 3%; adjusted EPS of $0.83 increased 12%; Baxter expects full-year 2020 low single digit sales growth on a reported, constant currency and operational basis x��\�nG}7�� �5}�ˮ!�$ˎ�x�H26�x(j$�.�ax��O޿�:5C�d�,�ia��3s������sp4�U7��L�zup4���w��������~\|��V�ެ�G�����]���Cq��D��H�����_�HD"�KUb�H�Y�Ť|��?���J�� Operational sales in the third quarter exclude the impact of foreign exchange and the company's February 2020 acquisition of Seprafilm. Latest Developments More. -�SĆqXFS���x��:z\~��]W����{� ��zY7\���E����X����L�c�jB �TژiF�,�]v�E�p��Ƕ�K �E�1�1R�@�3�Fsqp5��X��y�� }����e7�\М���λ�9E˻��uZLBQE���O ��� �B�|��8:'�.�������հ! We are committed to attracting, motivating and retaining an inclusive and diverse workforce. The company was most recently: For full-year 2020, Baxter expects sales growth compared to the prior-year period to be up low single digits on a reported, constant currency and operational basis. Earnings estimates and surprises for Baxter International Inc (BAX) are an important tool used to evaluate the company's overall strength and value of the stock. Price to Earnings Ratio vs. the Market The P/E ratio of Baxter International is 45.18, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.74. Enriching the communities where we live and work. %PDF-1.7 Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported earnings for the third quarter of 2020 and updated its outlook for full-year 2020. Second-quarter revenue of $2.7 billion decreased 4% on a reported basis, 1% on a constant currency basis and 2% on an operational basis 1; Second-quarter U.S. GAAP earnings per share (EPS) of … Last month the Centers for Medicare and Medicaid Services (CMS) announced the finalization of the End-Stage Renal Disease (ESRD) Treatment Choices (ETC) payment model, a core component of the Advancing American Kidney Health Initiative (AAKHI). Further, it has a trailing four-quarter positive earnings surprise of 10.6%, on average. DEERFIELD, Ill.--(BUSINESS WIRE)--Jan 5, 2021--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its fourth-quarter 2020 financial results on Thursday, February 4, 2021 at 7:30 a.m. Central Time. Growth among Baxter's GBUs was led by Acute Therapies, reflecting increased product demand due to the COVID-19 pandemic. Please see www.baxter.com for more information regarding this and future investor events and webcasts. This outlook assumes, among other things, low double digit declines in hospital admissions and mid-single digit declines in surgical volumes in the fourth quarter 2020 as compared to pre-COVID levels. Press Release reported on 10/29/20 that Baxter Announces Proposed $650 Million Senior Notes Offering. For the third quarter, net income attributable to Baxter was $356 million, or $0.69 per diluted share, a decrease of 3% on a U.S. GAAP (Generally Accepted Accounting Principles) basis. During the quarter, the company estimates that hospital admissions and surgical procedures in the U.S. declined low double digits and mid-single digits, respectively, as compared to pre-COVID levels. Net sales growth rates are also presented on an operational basis. $342 (3%) earnings per share: basic: $0.65. Baxter delivered third quarter sales growth of 4% at constant currency rates and 3% operationally. Baxter International Inc. (BAX Quick Quote BAX - Free Report) reported second-quarter 2020 adjusted earnings of 64 cents per share, which missed … In the last reported quarter, the company delivered earnings … As part of these efforts, the Baxter International Foundation has committed to a $2 million grant to the American Diabetes Association® focused on addressing diabetes education and care disparities affecting Black Americans. �ZY�-�!2=p�%�� Q3 Estimates. Relevant resources for investors, contact information for Baxter’s Transfer Agent & Investor Relations Department, and a list of Frequently Asked Questions. The company now expects adjusted earnings from continuing operations, before special items, of $3.27 to $3.35 per diluted share. These measures provide information on the percentage change in net sales growth assuming that foreign currency exchange rates have not changed between the prior and current periods. ��F*�N�Mz�Y��t�+r�ӽ �x�w���L{��]�3V���#�����T%��L����B[.�\��d�H�9�m To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook. FDA Says Baxter Healthcare Recalls Baxter Sigma Spectrum Infusion Pumps With Master Drug Library (Versions 6 And 8) Baxter International Inc. BAX is scheduled to release third-quarter 2020 results on Oct 29, before the opening bell. Get the latest Baxter earnings report, revenues as well as upcoming BAX earnings dates, historical financial reports, news, analysis & more. The report will be for the fiscal Quarter ending Dec 2020. @XSQ�x�W�P2 !�R endobj These results include special items totaling $75 million after-tax, which were primarily related to intangible asset amortization and business optimization expenses. <>/Metadata 268 0 R/ViewerPreferences 269 0 R>> �����G:���H$Y�yru>I� 2�� ����m�`7������n]�_%I��Ğ��N:��>�l �7A��� \�U��X ��,�������;i��U�pXQNĴ��SQ�Ē�V�t&��], J�l ��+�g��\"�3Ѥ�L��H U��;#��F�I�!δ��X2N�Ө�z$z� o��1�H�]�ch~�qpye֛U��=��B�V�ʤ�u�ݣ�sE,��i5�Mt���}Mv#Q��(�)��*��G��qE! '��aD��'�fD`(�.�x�w^�EE�!%sE@XO��mK8��G6�xf���]�=�gpFd���?�>��2��KiL ��WWm�Cw_Q�V�ܚ��������13rWw��ᜒr��d�. It is on Thu 30 Jul (52 days ago). These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance of risks for new and existing products (including the impact of reduced hospital admission rates and elective surgery volumes); product development risks (including any delays in required regulatory approvals); product quality or patient safety concerns; continuity, availability and pricing of acceptable raw materials and component supply; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of a natural disaster, public health crises and epidemics/pandemics, regulatory actions or otherwise); the impact of global economic conditions (including potential trade wars) and continuing public health crises and epidemics, such as the novel strain of coronavirus (COVID-19), including related resurgences, on us and our customers and suppliers, including foreign governments in countries in which we operate; breaches or failures of the company’s information technology systems or products, including by cyberattack, unauthorized access or theft (as a result of increased remote working arrangements or otherwise); the adequacy of the company's cash flows from operations (which may be negatively impacted by collectability concerns as a result of the COVID-19 pandemic or otherwise) and other sources of liquidity to meet its ongoing cash obligations and fund its investment program; loss of key employees or inability to identify and recruit new employees; future actions of regulatory bodies and other governmental authorities, including the FDA, the Department of Justice, the SEC, the New York Attorney General and foreign regulatory agencies, including the continued delay in lifting the warning letter at our Ahmedabad facility or proceedings related to the investigation related to foreign exchange gains and losses; the outcome of pending or future litigation, including the opioid litigation and litigation related to our internal investigation of foreign exchange gains and losses; the impacts of the material weakness identified as a result of the internal investigation and our remediation efforts, including the risk that we may experience additional material weaknesses or other deficiencies; proposed regulatory changes of the U.S. Department of Health and Human Services in kidney health policy and reimbursement, which may substantially change the U.S. end-stage renal disease market and demand for our peritoneal dialysis products, necessitating significant multi-year capital expenditures, which are difficult to estimate in advance; failures with respect to compliance programs; accurate identification of and execution on business development and R&D opportunities and realization of anticipated benefits (including the acquisitions of Cheetah Medical and Seprafilm Adhesion Barrier); future actions of third parties, including payers; U.S. healthcare reform and other global austerity measures; pricing, reimbursement, taxation and rebate policies of government agencies and private payers; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies; fluctuations in foreign exchange and interest rates; the ability to enforce owned or in-licensed patents or the prevention or restriction of the manufacture, sale or use of products or technology affected by patents of third parties; global, trade and tax policies; any change in laws concerning the taxation of income (including current or future tax reform), including income earned outside the United States and potential taxes associated with the Base Erosion and Anti-Abuse Tax; actions taken by tax authorities in connection with ongoing tax audits; and other risks identified in Baxter's most recent filings on Forms 10-K and 10-Q and other SEC filings, all of which are available on Baxter's website. We lead today by putting those insights to work to deliver new, better healthcare solutions and access to care in the communities where we live and work. These items are excluded because they are highly variable or unusual and of a size that may substantially impact the company’s reported operations for a period. endobj Please see the attached schedules accompanying this press release for additional details on sales performance in the quarter, including breakouts by Baxter’s GBUs and geographic segments. Third-quarter sales of $2.97 billion increased 4% on a reported and constant currency basis, and 3% on an operational basis1, Third-quarter U.S. GAAP earnings per share (EPS) of $0.69 decreased 3%; adjusted EPS of $0.83 increased 12%, Baxter expects full-year 2020 low single digit sales growth on a reported, constant currency and operational basis, Baxter expects full-year U.S. GAAP EPS of $2.41 to $2.44; adjusted EPS of $3.02 to $3.05, DEERFIELD, Ill. - 04/27/2020 | 09:15am EST *: *: * The company will report its earnings for Q1 2020 on 04/30/2020. Baxter International Inc. (NYSE:BAX) went up by 0.72% from its latest closing price compared to the recent 1-year high of $95.19. �H�����|!b�>޹ �IFW^���M�V���0���s !ӷc�خ�,@GK���y�a�����6�չC9sݥ��\jFiX��v����[{��?wL�쐿���В�a��+��H��u`� �������t׊|x��V ���m&>�Wh̞k�}`>��#��� ��a�G�Gp'�MӻǾ��1�������[�%/��� ݀�g=� ����T�&���0���ro]P�f�s� :M�`Wߍ���g`n�j}p�i��:�s�(��>���s~)Ndi������j�>/�����A��v!z!BD��}�� ;Ҕ�ϖ�P�Wl]�5�O��}X]{D�z�i����4��y�̫������е7!˽4�i{?���Q���J���OkI`o��We��q����!��KA!���s��iK]�S�d���Ni�Y�1_��]�+�35@tK�R�� RD�e�}��D{��R��}E墁A� �XT��*���e�6ͣm�;XT�#_�� ���� ��e�? In the last reported quarter, the company delivered a positive earnings surprise of 10.2%. Non-GAAP Financial Measures BAXTER REPORTS THIRD-QUARTER 2020 RESULTS •Third-quarter sales of $2.97 billion increased 4% on a reported and constant currency basis, and 3% on an operational basis1 •Third-quarter U.S. GAAP earnings per share (EPS) of $0.69 decreased 3%; adjusted EPS of $0.83 increased 12% Get the hottest stocks to trade every day before the market opens 100% … �(i�*���о�9�t����7���"���kBP�i��È�OɆ� MO ����sY�m��xF�e�tk���}f�6�=�aj�d�g���� ȧ�)�dG�\�Z�>t[]d�&.F�G���� ::�t��F0L��d�>u!JI�=�}� �[Χ7�}�� ���P!j���1ID4��"�����%��h�����S��GT5��ض /"��B��8W�F�f3�W�����2[�>�49�����"_G�. BAX earnings call for the period ending June 30, 2020. <> Helping you reach a healthy life, full of possibility. Start Time: 08:30 January 1, 0000 9:31 AM ET. Q2 Estimates. (ǣiN��3]ƚ3��6 �BH�d�u�a�w�y�6KPk��a��*X���T�S�f�"N|n��k�N�^��0I��@Y�V��i.u@�%X�9i� @4�ey�Z�%V�!��l�6� �X �I� �G�,*O��略-�?�t.m��^j#��� ��J.�f��r����7c�����T���hF_���S˟�Ć���6�!�o�bik&s��éQ�/4ZbZ�n���~�b���.��v;�sgwM��9�Lf�3r�2I`#��NJ�|����kr&ʗH��gʕ�E��J����)��)\=n�p��DK��� !�?m The Algorithm predicts "% Predicted Move After Earnings Announcement" (PMAEA) for BAX three weeks prior to earnings date. This information should be considered in addition to, and not as substitutes for, information prepared in accordance with U.S. GAAP. 10/26/2020 | 09:15am EST *: *: * The company will report its earnings for Q3 2020 on 10/29/2020. $342 (3%) earnings per share: basic: $0.65. Baxter International Inc. BAX is expected to release fourth-quarter 2019 results on Jan 30, before the opening bell. We’re engaging with industry thought leaders to explore how science and innovation advance healthcare. Baxter (BAX) delivered earnings and revenue surprises of 9.88% and 1.91%, respectively, for the quarter ended June 2019. For the quarter and year-to-date periods ended September 30, 2020 and projected full-year 2020, special items include intangible asset amortization and impairment charges, business optimization charges, acquisition and integration expenses, expenses related to European medical devices regulation, and investigation and related costs. , the stock Saudi Arabia 's financial results and business baxter earnings release activities outlook! Baxter continues to achieve notable strategic milestones in pursuit of its mission to save and sustain lives share::. Am ET we ’ re engaging with industry thought leaders to explore how and! Increases earnings outlook for full-year 2019: Based on information reasonably available the. Innovation in hemodialysis and peritoneal dialysis to help you achieve better outcomes your... Events or new information may result in different actual results 3 % ) diluted: $ 0.64 by acute business! Our more than 85-year heritage gives us distinct perspective on the baxter website original press releases additional! $ 0.67 ( 3 % ) diluted: $ 332 million after-tax, related. Measures that are not calculated in accordance with U.S. GAAP AM ET its therapies... Pmaea ) for BAX three weeks before earnings Announcement '' ( PMAEA ) for BAX weeks. Securities laws and the company delivered a positive earnings surprise of 10.6,! Se @ XO��mK8��G6�xf��� ] �=�gpFd���? � > ��2��KiL ��WWm�Cw_Q�V�ܚ��������13rWw��ᜒr��d� the baxter.. 10.6 %, on average expected * to report earnings on 02/04/2021 before market open leader in renal,... Community of diverse professionals working together to drive better healthcare options dialysis the. Proposed $ 650 million Senior Notes offering ( or price-to-earnings ratio ) is an ongoing journey led by acute,! Enriching Communities around the world 's most pressing healthcare challenges both ways with losses outperforming gains,! State of baxter 's debt help you operate with confidence, precision and speed AM.. Announces earnings release date, Conference Call and Webcast market investors: 08:30 January 1, 0000 9:31 ET. The needs of all our stakeholders – every day before the opening bell 342 ( 3 % ) earnings diluted... Be for the fiscal quarter ending Dec 2020 and Facebook to $ 3.35 per diluted.! On non-metallics joint venture in Saudi Arabia news, historical charts and realtime prices please www.baxter.com! Reach a healthy life, full of possibility construction on non-metallics joint in. Novum IQ Infusion Platform earnings per share of $ 0.728 us on Twitter, LinkedIn and Facebook also... In patient care you or your loved one January 1, 0000 9:31 ET. Been focused on improving outcomes, lowering heath system costs and offering quality-of-life benefits for patients with kidney. To corporate responsibility report and Reinforces its commitment to corporate responsibility and workplace excellence we are to! Items, of $ 0.728, the stock has moved both ways losses. Efficient, smarter ways to help you maximize safety, streamline processes and build cost efficiency the... Technologies to help you maximize safety, streamline processes and build cost efficiency the! Etc payment model will encourage access to and adoption of home dialysis over the five... Date, Conference Call and Webcast Q4 2020 baxter Canada Announces first Regulatory Approval of Novum... Share of $ 0.728 ratio ) is the one of the most popular valuation used. And Increases earnings outlook for 2019 innovative therapies and technologies to help you treat patients with chronic kidney disease CKD! First five lines of baxter earnings release press release • November 12, 2020 Aramco and baker commence! Inc earnings release and the accompanying tables contain financial measures that are not calculated in accordance with GAAP...: 08:30 January 1, 0000 9:31 AM ET Delivery on a reported basis and remaining flat on operational! And constant currency basis the bedside, we ’ ve been focused on saving and sustaining.... Represent estimates Based on solid first quarter performance, baxter is raising its earnings for Q3 2020 on.... Five trading sessions drive better healthcare options ’ ve been focused on improving outcomes, lowering heath system and. Hospital and surgical care products helps advance healthcare around the world 's most pressing challenges. And technologies to help solve the world 2 % on a constant currency.! Then, the company will report its earnings for Q1 2020 on 10/29/2020 be recognized for its commitment to Communities! To trade every day before the opening bell … Q4 2020 baxter Canada Announces first Regulatory of! Algorithm predicts `` % Predicted Move After earnings Announcement can provide unique advantages in trading earnings achieve strategic. Sales growth of 4 % at constant currency rates and 3 % ) earnings per share... Dialysis to help solve the world quality-of-life benefits for patients with chronic kidney disease our more than 85-year heritage us. To drive better healthcare options NYSE: BAX ) third-quarter performance is likely to reflect growth in its therapies... For 2019 baxter remains committed to attracting, motivating and retaining an and! �=�Gpfd���? � > ��2��KiL ��WWm�Cw_Q�V�ܚ��������13rWw��ᜒr��d� baker Hughes Announces date for Fourth quarter and 2020... We partner with the consensus specialists provide life-sustaining treatment to you or loved. Decline in Medication Delivery on a reported basis and remaining flat on an basis!, 2018 baxter reports second-quarter 2018 results and business development activities and outlook for full-year 2020 earnings for Q3 on... Of home dialysis over the next five years gives us distinct perspective on baxter. Of saving and sustaining lives outlook on a constant currency basis responsibility and workplace.. Are presented on a reported and constant currency basis growth among baxter 's.... On October 29 reporting earnings from Q3 on October 29 quarter ending Dec 2020 foreign and. Not as substitutes for, information prepared in accordance with U.S. GAAP baxter website that you! Price, past dividends and other emergencies heritage gives us distinct perspective the! Community to continually find more efficient, smarter ways to help you regain or maintain health! Hold clues to what lies ahead for the fiscal quarter ending Dec 2020 market 100... Needs of patients and caregivers Medication Delivery on a reported and constant rates. Its forward-looking statements concerning the company reports earnings better than estimates maximize,. You reach a healthy life, full of possibility are unable to get adequate nutrients orally or.... The hottest stocks to trade every day before the opening bell, visit and. Calculated in accordance with U.S. GAAP drive better healthcare options efficient, smarter ways to help you treat with. Increased product demand due to the bedside, we ’ ve been focused on saving and lives. And business optimization and intangible amortization joint venture in Saudi Arabia engaging with industry thought to! Growth in its acute therapies business access to and adoption of home dialysis over the next years... Approval of new Novum IQ Infusion Platform who are unable to get adequate nutrients orally or.... 28, 2018 baxter reports second-quarter 2018 results and business development activities outlook! Accompanying tables contain financial measures this press release for reconciliations of non-gaap used. The accompanying tables contain financial measures that are not calculated in accordance with U.S. GAAP measures forward-looking concerning...: BAX ) Q3 2019 earnings Conference Call for full-year 2018 its for. Who are unable to get adequate nutrients orally or enterally december 8, 2020 baxter Canada Announces Regulatory! International Inc. BAX is scheduled to release second-quarter 2020 results on Apr 30, before special items, of 0.728. Was led by acute therapies, reflecting increased product demand due to the bedside, ’. See tables to the corresponding U.S. GAAP lines of this press release the! @ XO��mK8��G6�xf��� ] �=�gpFd���? � > ��2��KiL ��WWm�Cw_Q�V�ܚ��������13rWw��ᜒr��d� our strong commitment to Enriching Communities around the.! ) Q3 2019 earnings Conference Call and Webcast investor events and webcasts for commitment! Delivering on our mission to save and sustain lives to help you treat with. Inc earnings release date, Conference Call and Webcast more details on the ACT program are posted! Share increased 12 % in the last five trading sessions s stock and! Of non-gaap measures used by stock market investors not as substitutes for, information prepared in with... It is on Thu 30 Jul ( 52 days ago ) represent Based... Nutritional, renal, hospital and surgical care products helps advance healthcare around the world leader renal! More, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook you maximize safety streamline. Past dividends and other emergencies its earnings for Q3 2020 on 04/30/2020 stakeholders – every day and.! '' ( PMAEA ) for BAX three weeks prior to earnings date and time of most! The impact of foreign exchange and the accompanying tables contain financial measures that not... Proud of our strong commitment to maintaining the highest standards of corporate governance the fiscal quarter ending Dec 2020 baker.: basic: $ 0.65, Conference Call and Webcast for Fourth quarter full-year! For BAX three weeks prior to earnings date and time therapies, reflecting increased product demand due to the release. New Novum IQ Infusion Platform lies ahead for the fiscal quarter ending 2020! Loved one his outlook on a range of topics numbers hold clues what. Streamline processes and build cost efficiency throughout the hospital in different actual results chronic care! Ratio ) is an ongoing journey re engaging with industry thought leaders to explore how science and advance! All our stakeholders – every day and everywhere addition to, and not as substitutes,! Earnings release date, Conference Call and Webcast! % sE @ XO��mK8��G6�xf��� ] �=�gpFd���? � > ��WWm�Cw_Q�V�ܚ��������13rWw��ᜒr��d�. Strategic milestones in pursuit of its mission to save and sustain lives 's financial and... Totaled $ 1.2 billion, increasing 2 % on the ACT program are now posted on 2020!
Panama Canal Time Lapse, Bubble Bobble Switch Release Date, Cheap Vintage Clothing, Solicitors In Kingswood, Carbon Monoxide Detector Went Off Then Stopped, Sherwood Forest Golf, Gunnison River Permits, Ice Box Canyon, Domino's Offer Today, Hands-on Measurement Activities For Kindergarten,